← Back to AVTX

Avalo Therapeutics, Inc. - Common Stock financial statements

Annual and standalone quarterly facts filed by the company with the SEC. Monetary values are shown in USD millions; per-share values use USD.

Filed statements

USD; millions except EPSJun 2026Filed 06/08/2026Mar 2026Filed 13/05/2026Sep 2025Filed 06/11/2025Jun 2025Filed 06/08/2026Mar 2025Filed 13/05/2026Sep 2024Filed 06/11/2025Jun 2024Filed 07/08/2025Mar 2024Filed 12/05/2025
$0$0.2$0$0
−$36−$20−$31−$21−$13$23$98−$121
−$0.83−$0.98−$2.19−$1.92−$1.25−$2.83−$14.07−$141.14
4420141111117.70.9

Trend

Revenue

Source: SEC EDGAR Company Facts. Values are normalized from issuer-filed US GAAP or IFRS XBRL facts. Missing cells stay missing; cumulative interim cash flows are not converted into estimated quarters.